525 related articles for article (PubMed ID: 25436828)
1. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
[TBL] [Abstract][Full Text] [Related]
2. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
[TBL] [Abstract][Full Text] [Related]
3. Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.
Netto JP; Schwartz D; Varallyay C; Fu R; Hamilton B; Neuwelt EA
Fluids Barriers CNS; 2016 Dec; 13(1):23. PubMed ID: 27998280
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of grade II/III and grade IV glioma by combining "T1 contrast-enhanced brain perfusion imaging" and susceptibility-weighted quantitative imaging.
Saini J; Gupta PK; Sahoo P; Singh A; Patir R; Ahlawat S; Beniwal M; Thennarasu K; Santosh V; Gupta RK
Neuroradiology; 2018 Jan; 60(1):43-50. PubMed ID: 29090331
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Values of DCE-MRI and DSC-MRI for Differentiation Between High-grade and Low-grade Gliomas: A Comprehensive Meta-analysis.
Liang J; Liu D; Gao P; Zhang D; Chen H; Shi C; Luo L
Acad Radiol; 2018 Mar; 25(3):338-348. PubMed ID: 29223713
[TBL] [Abstract][Full Text] [Related]
6. Tumor recurrence versus treatment effects in glioma: A comparative study of three dimensional pseudo-continuous arterial spin labeling and dynamic susceptibility contrast imaging.
Xu Q; Liu Q; Ge H; Ge X; Wu J; Qu J; Xu K
Medicine (Baltimore); 2017 Dec; 96(50):e9332. PubMed ID: 29390403
[TBL] [Abstract][Full Text] [Related]
7. Diffusion kurtosis imaging combined with dynamic susceptibility contrast-enhanced MRI in differentiating high-grade glioma recurrence from pseudoprogression.
Shi W; Qu C; Wang X; Liang X; Tan Y; Zhang H
Eur J Radiol; 2021 Nov; 144():109941. PubMed ID: 34735828
[TBL] [Abstract][Full Text] [Related]
8. Visual inspection of MR relative cerebral blood volume maps has limited value for distinguishing progression from pseudoprogression in glioblastoma multiforme patients.
Kerkhof M; Tans PL; Hagenbeek RE; Lycklama À Nijeholt GJ; Holla FK; Postma TJ; Straathof CS; Dirven L; Taphoorn MJ; Vos MJ
CNS Oncol; 2017 Oct; 6(4):297-306. PubMed ID: 28984142
[TBL] [Abstract][Full Text] [Related]
9. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
10. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.
Tsien C; Galbán CJ; Chenevert TL; Johnson TD; Hamstra DA; Sundgren PC; Junck L; Meyer CR; Rehemtulla A; Lawrence T; Ross BD
J Clin Oncol; 2010 May; 28(13):2293-9. PubMed ID: 20368564
[TBL] [Abstract][Full Text] [Related]
11. Treatment monitoring in gliomas: comparison of dynamic susceptibility-weighted contrast-enhanced and spectroscopic MRI techniques for identifying treatment failure.
Vöglein J; Tüttenberg J; Weimer M; Gerigk L; Kauczor HU; Essig M; Weber MA
Invest Radiol; 2011 Jun; 46(6):390-400. PubMed ID: 21285888
[TBL] [Abstract][Full Text] [Related]
12. Amide proton transfer imaging to discriminate between low- and high-grade gliomas: added value to apparent diffusion coefficient and relative cerebral blood volume.
Choi YS; Ahn SS; Lee SK; Chang JH; Kang SG; Kim SH; Zhou J
Eur Radiol; 2017 Aug; 27(8):3181-3189. PubMed ID: 28116517
[TBL] [Abstract][Full Text] [Related]
13. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Diffusion Tensor Imaging and Magnetic Resonance Perfusion Imaging in Differentiating Recurrent Brain Neoplasm From Radiation Necrosis.
Masch WR; Wang PI; Chenevert TL; Junck L; Tsien C; Heth JA; Sundgren PC
Acad Radiol; 2016 May; 23(5):569-76. PubMed ID: 26916251
[TBL] [Abstract][Full Text] [Related]
15. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI.
Kim YH; Oh SW; Lim YJ; Park CK; Lee SH; Kang KW; Jung HW; Chang KH
Clin Neurol Neurosurg; 2010 Nov; 112(9):758-65. PubMed ID: 20619531
[TBL] [Abstract][Full Text] [Related]
16. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.
Hu LS; Baxter LC; Smith KA; Feuerstein BG; Karis JP; Eschbacher JM; Coons SW; Nakaji P; Yeh RF; Debbins J; Heiserman JE
AJNR Am J Neuroradiol; 2009 Mar; 30(3):552-8. PubMed ID: 19056837
[TBL] [Abstract][Full Text] [Related]
17. The use of (18)F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma.
Dankbaar JW; Snijders TJ; Robe PA; Seute T; Eppinga W; Hendrikse J; De Keizer B
J Neurooncol; 2015 Oct; 125(1):167-75. PubMed ID: 26384811
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Different Post-Processing Algorithms for Dynamic Susceptibility Contrast Perfusion Imaging of Cerebral Gliomas.
Kudo K; Uwano I; Hirai T; Murakami R; Nakamura H; Fujima N; Yamashita F; Goodwin J; Higuchi S; Sasaki M
Magn Reson Med Sci; 2017 Apr; 16(2):129-136. PubMed ID: 27646457
[TBL] [Abstract][Full Text] [Related]
19. Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
Prager AJ; Martinez N; Beal K; Omuro A; Zhang Z; Young RJ
AJNR Am J Neuroradiol; 2015 May; 36(5):877-85. PubMed ID: 25593202
[TBL] [Abstract][Full Text] [Related]
20. Prospective comparative diagnostic accuracy evaluation of dynamic contrast-enhanced (DCE) vs. dynamic susceptibility contrast (DSC) MR perfusion in differentiating tumor recurrence from radiation necrosis in treated high-grade gliomas.
Zakhari N; Taccone MS; Torres CH; Chakraborty S; Sinclair J; Woulfe J; Jansen GH; Cron GO; Thornhill RE; McInnes MDF; Nguyen TB
J Magn Reson Imaging; 2019 Aug; 50(2):573-582. PubMed ID: 30614146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
